WuXi XDC Cayman (STU:L74) Current Deferred Revenue: €0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:L74 WuXi XDC Cayman Inc STU:L74
50 GF Score
Price €7.50
! 3 Warning Signs
View Full Analysis

What is WuXi XDC Cayman Current Deferred Revenue?

WuXi XDC Cayman STU:L74 -5.06% 50 Current Deferred Revenue is €0.0 Mil as of Dec. 2025. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

WuXi XDC Cayman's current deferred revenue for the quarter that ended in Dec. 2025 was €0.0 Mil.

WuXi XDC Cayman Current Deferred Revenue Related Terms

WuXi XDC Cayman Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for WuXi XDC Cayman's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi XDC Cayman Current Deferred Revenue Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

WuXi XDC Cayman Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:L74
50GF Score
WuXi XDC Cayman Inc STU:L74
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.0 Mil mean?
WuXi XDC Cayman (STU:L74) has a Current Deferred Revenue of €0.0 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on WuXi XDC Cayman and its competitors.
Is WuXi XDC Cayman's Current Deferred Revenue too high?
WuXi XDC Cayman's current Current Deferred Revenue is €0.0 Mil. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Current Deferred Revenue compare to TMO and DHR?
WuXi XDC Cayman's Current Deferred Revenue of €0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current Current Deferred Revenue is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current Current Deferred Revenue of €0.0 Mil. The current Current Deferred Revenue is €0.0 Mil. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current Current Deferred Revenue is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

WuXi XDC Cayman Business Description

Other Exchanges 02268:Hong KongL74:Germany
Address No. 11 Xinhui Ring Road, Xinwu, Jiangsu Province, Wuxi, CHN
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score

Get the complete analysis for STU:L74

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.50
Price